Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest
Key facts
- Who runs it
- Invero Pharma, Inc.
- Where
- Buffalo, Columbus, Gainesville, Gulfport, Hartford, Houston, Memphis, and Omaha, United StatesSee the 8 sitesAlso in 1 other country, 2 sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 1,436 people, planned
- Started
- Mar 2026
- Expected to end
- May 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Xenon
- Record updated
- 3 April 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Age at least 18 years but less than or equal to 80 years
- Presumed cardiac cause of arrest
- Sustained (>20 minutes) spontaneous circulation upon arrival in the emergency department
- No response to verbal commands on arrival to emergency department and prior to randomization (Glasgow Coma Scale score of <8)
- Attending decision that patient is eligible for TTM
Who cannot take part
- Traumatic etiology of arrest, defined as concomitant blunt, penetrating, or burn-related injury, or uncontrolled bleeding or exsanguination
- Bed-bound prior to cardiac arrest
- Have received an investigational drug, device, or biologic product within 30-days
- Suspected or known stroke or intracranial hemorrhage
- Unwitnessed cardiac arrest
- No-flow (cardiac arrest to initiation of cardiopulmonary resuscitation/defibrillation) time of >10 minutes
- Unconsciousness before cardiac arrest (cerebral trauma, spontaneous cerebral hemorrhage, intoxication etc.)
- Known terminal phase of chronic illness
- Have any condition that would impact the evaluation of modified Rankin Scale (mRS)
- Having any other clinically significant laboratory abnormality, medical condition (such as intrinsic liver disease or severe chronic obstructive pulmonary disease), or social circumstance that, in the investigator's opinion, makes it inappropriate for the patient to participate in this clinical trial
- Written do not attempt resuscitation reported to providers before randomization
- Sustained restoration of spontaneous circulation (ROSC) greater than 30- minutes post-arrest
- Interval from arrival at the emergency department to randomization for intervention of >4 hours
- Hypothermia (<30°C core temperature)
- Coagulopathy
- Systolic arterial pressure <80 mmHg or mean arterial pressure <60 mmHg lasting more than 30 minutes after ROSC
- Known pregnancy
- Hypoxemia (SaO2 <85%) for >15 minutes after ROSC
- Inability to maintain SaO2 >90% on an FiO2 of 50%
- Logistically impossible to provide intervention
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
Also in 1 other country, 2 sites
- University at BuffaloBuffalo, United StatesContact: Robin M. Stein, RN, BSNNot yet recruiting
- Wexner Medical Center, Ohio State UniversityColumbus, United StatesContact: January Kim, BSNot yet recruiting
- University of FloridaGainesville, United StatesContact: Clinical Trial Support at Invero PharmaNot yet recruiting
- Memorial Hospital at GulfportGulfport, United StatesContact: Brandy WilliamsNot yet recruiting
- Hartford HospitalHartford, United StatesContact: William RomanNot yet recruiting
- Houston Methodist Research InstituteHouston, United StatesContact: Digant JariwalaNot yet recruiting
- Baptist Memorial Hospital, Baptist Clinical Research InstituteMemphis, United StatesContact: Mildred JenkinsNot yet recruiting
- University Nebraska Medical CenterOmaha, United StatesContact: Lace D Sindt, BSNot yet recruiting
About the trial
What the trial wants to find out
XePOHCAS: Prospective, randomized, multicenter interventional trial in adult subjects with out-of-hospital cardiac arrest comparing treatment with standard-of-care post-cardiac arrest intensive care (which is targeted temperature management [TTM]) to xenon by inhalation plus standard-of-care post-cardiac arrest intensive care (including TTM).
The 2 groups in the trial
- TH/TTMNo study treatment, for comparison
Protocol-directed standard of care (including TH/TTM) dictated by the 2015 guidelines for Post-Cardiac Arrest Care from the American Heart Association and the European Resuscitation Council. Mechanical Ventilation delivered by individual site-sanctioned ventilator.
- TH/TTM plus XenonExisting treatment, for comparison
50% xenon gas in addition to standard of care, including therapeutic hypothermia/targeted temperature management (TH/TTM).
Treatment: Xenon
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- XePOHCAS - Xenon by Inhalation for Post Out of Hospital Cardiac Arrest Syndrome
- Criteria questions
- Built from NCT03176186, who can take part
- Publications
- Inhaled gases as novel neuroprotective therapies in the postcardiac arrest period.Current opinion in critical care, 2021
- Record updated
- 3 April 2025